355 results on '"Merchant K"'
Search Results
2. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
3. Discriminatory accuracy of the SOFA score for determining clinical decompensation in patients presenting with COVID-19
4. Predictors of clinical decompensation in patients presenting with COVID-19 in an urban hospital health system
5. Frequency selected ultrafast infrared vibrational echo studies of liquids, glasses, and proteins
6. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials
7. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study
8. Invasion of the Mold, a Diagnostic Dilemma
9. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial
10. CHARACTERIZATION OF KINASE ACTIVITY AND TOXICITY OF LEUCINE-RICH REPEAT KINASE 2: C13–02
11. Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
12. Unusual sequel to a known complication
13. Tolerability and Efficacy of Ropinirole in Patients with Intermittent Restless Legs Syndrome (RLS): Open-Label Results: Poster 17 (OMD)
14. Rapid habituation of hippocampal serotonin and norepinephrine release and anxiety-related behaviors, but not plasma corticosterone levels, to repeated footshock stress in rats
15. Management Change in Companies: A Comment
16. Dynamics in globular proteins: vibrational echo experiments
17. Improving conduct and feasibility of clinical trials to evaluate antibacterial drugs to treat hospital acquired bacterial pneumonia (HABP) and ventilator associated bacterial pneumonia (VABP): recommendations of the CTTI Antibacterial Drug Development (abdd) Project Team
18. Streamlining safety data collection in hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) trials: recommendations of the CTTI Antibacterial Drug Development (ABDD) Project Team
19. Sociology of Blackmarketing
20. Symposium on: Social Conditions and Creative Activity
21. Molecular Basis of the Anti-Cancer Effects of Genistein Isoflavone in LNCaP Prostate Cancer Cells
22. Stillbirths: Recall to action in high-income countries.
23. Effectiveness of the present ROP screening protocol
24. Sistemi di controllo di gestione: misure di performance, valutazione e incentivi
25. Il bilancio. Analisi economiche per le decisioni e la comunicazione della performance
26. Sistemi di controllo. Analisi economiche per le decisioni aziendali
27. Payments to Auditors: Likely Effect on Objectivity
28. Institutional Intervention in Company Affairs
29. Sistemi di controllo: Analisi economiche per le decisioni aziendali. 3a edizione
30. Physical factors affecting the corrosion resistance of CoCr thin-film media.
31. The mGlu2/3 Receptor Agonists LY354740 and LY379268 Differentially Regulate Restraint-Stress-Induced Expression of c-Fos in Rat Cerebral Cortex
32. Two-Dimensional Time-Frequency Ultrafast Infrared Vibrational Echo Spectroscopy
33. Il controllo di gestione
34. G&A gets the mix right
35. Control of international joint ventures
36. A review of the literature on control and accountability
37. Therapeutic efficacy of Genistein-Cytoreg® combination in breast cancer cells
38. 645 RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT
39. Genistein Modulation of Immune-Associated Genes in LNCaP Prostate Cancer Cell Line
40. Molecular basis of the anti-cancer effects of genistein isoflavone in LNCaP prostate cancer cells
41. 109 LONG TERM EFFICACY AND SURVIVAL IN PATIENTS TREATED WITH THE GUT-SELECTIVE ANTIBIOTIC RIFAXIMIN (550 MG BID) FOR THE MAINTENANCE OF REMISSION FROM OVERT HEPATIC ENCEPHALOPATHY
42. ChemInform Abstract: Synthesis and Biological Activity of 1,2,4-Oxadiazole Derivatives: Highly Potent and Efficacious Agonists for Cortical Muscarinic Receptors.
43. ChemInform Abstract: The Synthesis of 5- and 6-Substituted Quinuclidine-3-carboxylic Esters: Intermediates for Novel Muscarinic Ligands.
44. ChemInform Abstract: Synthesis of Homochiral Ketones Derived from L-Tryptophan: Potent Substance P Receptor Antagonists.
45. ChemInform Abstract: Identification of a Series of 3-(Benzyloxy)-1-azabicyclo(2.2.2)octane Human NK1 Antagonists.
46. 195 RIFAXIMIN DECREASES VENOUS AMMONIA CONCENTRATIONS AND TIME-WEIGHTED AVERAGE AMMONIA CONCENTRATIONS CORRELATE WITH OVERT HEPATIC ENCEPHALOPATHY (HE) AS ASSESSED BY CONN SCORE IN A 6-MONTH STUDY
47. 15 RIFAXIMIN TREATMENT IMPROVED QUALITY OF LIFE IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
48. 222 CHRONIC ADMINISTRATION OF RIFAXIMIN FOR THE MAINTENANCE OF REMISSION OF HEPATIC ENCEPHALOPATHY: A SUBGROUP ANALYSIS OF A PHASE 3 TRIAL
49. 93 RIFAXIMIN IS EFFECTIVE IN MAINTAINING REMISSION IN HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
50. 207 SAFETY OF RIFAXIMIN IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A RANDOMIZED, PHASE 3, PLACEBO-CONTROLLED CLINICAL TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.